Latest News
Incyte Corporation
- Incyte Corporation Estimates – NASDAQ:INCY
- Morgan Stanley initiates Incyte stock coverage with Equalweight rating By Investing.com
- Spotlight On: Niktimvo's IPF miss adds to mounting pressure on Incyte
- Why is Incyte stock down 2.8% today?
- Syndax, Incyte bin lung fibrosis programme for Niktimvo after Phase II miss
- Incyte Corp. stock underperforms Tuesday when compared to competitors
- Incyte Corp. stock underperforms Tuesday when compared to competitors
- Incyte shares drop more than 3% after FDA approval for Atebrioz fails to lift sentiment
- Diabetes tech company MiniMed hires ex-Incyte GC as next legal head
- Incyte patents new VRK1 inhibitors
- Delhi HC Temporarily Restrains Melody Healthcare From Selling Ruxolitinib Products In Incyte Patent Case
- Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz
Headlines from the last 30 days, linking to the original publishers. See all market news →